Press Release Service
Epic Bio to Participate in the Guggenheim...
Mar. 29, 2023
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Epic Bio
Main focus: CRISPR-based epigenetic engineering
Company stage: Pre-clinical
Diseases (gene editing): Facioscapulohumeral Muscular Dystrophy (FSHD), Heterozygous Familial Hypercholesterolemia (HeFH), Alpha-1 Antitrypsin Deficiency (A1AD), Retinitis Pigmentosa 4 (RP4), Retinitis Pigmentosa 11 (RP11)
Genome editing tool: CRISPR activation/CRISPR inhibition
Funding stage: Private
Location: South San Francisco, CA, USA
Website: https://epic-bio.com/
Pipeline: https://epic-bio.com/pipeline/
Epic Bio is a start-up company focused on epigenetic engineering using the CRISPR-Cas system. The company holds an exclusive license to a Cas enzyme called CasMINI, which is the smallest and most deliverable dCas protein to date, which can then be engineered with a modulating protein to attain activating- or inhibitory effects.
